Connect Biopharma Holdings Limited Ordinary Shares (CNTB)

Connect Biopharma will present two poster presentations at the ERS Congress 2025 about rademikibart, a monoclonal antibody targeting IL-4Rα for treating asthma and inflammatory diseases.

Connect Biopharma reported a significant revenue drop from $24.1 million to $48,000 in Q2 2025, increased R&D expenses, and a net loss of $12.9 million. The company continues developing rademikibart for inflammatory diseases and is progressing clinical trials.

Here is how Bausch Health (BHC) and Connect Biopharma Holdings Limited Sponsored ADR (CNTB) have performed compared to their sector so far this year.

Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. Icosavax also reported topline interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults. Icosavax shares gained 44.8% to $15.19 in ...

Use these tips to develop a penny stocks risk management strategy The post How to Develop a Penny Stocks Risk Management Strategy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.